Opaleye Management’s Viking Therapeutics VKTX Stock Holding History

Opaleye Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-400,000	Closed	-$3.32M	–	56
2019 Q2	$3.32M	Sell	400,000 -85,000	-18%	-$726K	1.01%	33
2019 Q1	$4.82M	Sell	485,000 -340,000	-41%	-$2.85M	1.34%	31
2018 Q4	$6.31M	Hold	825,000	–	–	2.36%	12
2018 Q3	$14.4M	Sell	825,000 -375,000	-31%	-$4.46M	3.66%	8
2018 Q2	$11.4M	Buy	1,200,000 +99,200	+9%	+$660K	2.95%	8
2018 Q1	$4.81M	Buy	1,100,800 +620,242	+129%	+$3.43M	1.38%	23
2017 Q4	$1.95M	Buy	+480,558	New	+$1.4M	0.62%	27

Other funds holding VKTX

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Opaleye Management's VKTX Position: Q3 2019 in Review

Opaleye Management sold out of Viking Therapeutics (VKTX) in Q3 2019, closing a stake of 400,000 shares — an estimated $3.32M sold.

Opaleye Management first reported a position in VKTX in Q4 2017 and held it in 7 quarters. The position peaked at $14.4M in Q3 2018. 144 funds tracked by Wall St. Rank hold VKTX as of Q3 2019.

Opaleye Management reported no remaining Viking Therapeutics position as of Q3 2019 after selling out during the quarter.
Opaleye Management sold 400,000 Viking Therapeutics shares in Q3 2019, an estimated $3.32M.
Opaleye Management first reported a position in Viking Therapeutics in Q4 2017 and held it in 7 quarters.
Opaleye Management's Viking Therapeutics position peaked at $14.4M in Q3 2018.
144 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2019.

Based on Opaleye Management's 13F filing for Q3 2019, filed 14 Nov 2019.